6-Aminophenyl- and 6-Acylaminophenyl-4,5-Dihydropyridazones-(3) and their production

    公开(公告)号:GB1164139A

    公开(公告)日:1969-09-17

    申请号:GB5812266

    申请日:1966-12-29

    Applicant: BASF AG

    Abstract: 1,164,139. Dihydropyridazone derivatives. BADISCHE ANILIN- & SODA-FABRIK A.G. 29 Dec., 1966 [19 Oct., 1966], No. 58122/66. Heading C2C. Novel compounds of formula where R is amino or is acylamino having 2 to 12 C atoms and optionally derived from a polybasic acid, are prepared by reaction of hydrazine with a compound of formula wherein R 11 is OH or alkoxy and R 1 is R or a group convertible to R, and if necessary converting R 1 to R. The novel compounds have anti-inflammatory and blood pressure reducing action.

    12.
    发明专利
    未知

    公开(公告)号:FR1507475A

    公开(公告)日:1967-12-29

    申请号:FR89952

    申请日:1967-01-04

    Applicant: BASF AG

    Abstract: 1,168,291. Pyridazones. BADISOHE ANILIN- & SODA-FABRIK A.G. 6 Jan., 1967, [7 Jan., 1966], No. 925/67. Heading C2C. Novel 6-aminophenyl-3-pyridazones of the Formula I wherein X is a hydrogen or halogen atom or an alkyl or alkoxy group and each of R 1 and R 2 is a hydrogen atom or an alkyl group, any alkyl groups in the substituents being optionally substituted by halogen atoms or hydroxyl groups, are obtained by dehydrogenating the corresponding 6 - aminophenyl - 4,5 - dihydro - 3- pyridazones, in which the radical R 1 may additionally represent an aliphatic or aromatic acyl group, using aromatic nitrosulphonic acids or salts thereof as dehydrogenating agents, the molar ratio of pyridazone to nitrosulphonic derivative being up to 1 : 0À5 per nitro group in the latter.

    New halogen-containing therapeutic carbamic acid esters and their production

    公开(公告)号:GB958616A

    公开(公告)日:1964-05-21

    申请号:GB646462

    申请日:1962-02-20

    Applicant: BASF AG

    Abstract: The invention comprises compounds of general formula: in which R1 denotes an alkyl, substituted alkyl, cycloalkyl, aryl, aralkyl, amino, substituted amino, carbamyl, substituted carbamyl or heterocyclic radical, R2 denotes a hydrogen atom or an alkyl, substituted alkyl or aryl radical, or in which R1 and R2 together with the amide nitrogen atom may form a heterocyclic ring, and in which X1, X2, X3 are each halogen atoms; and their preparation by introducing the radical -CO-NR1R2 into a pentaerythritol trihalohydrin of general formula: to replace the hydroxyl hydrogen thereof by reacting said pentaerythritol trihalohydrin with a carbamic acid halide of general formula: Hal-CO-NR1R2, or with phosgene and then with an amine of general formula HNR1R2, or (when R2=H) with an isocyanate of general formula OCN-R1. Other processes described are reaction of a pentaerythritol trihalohydrin with (1) a urethane R3O.OC-NR1R2, or (2) a haloformic acid ester Ha1-CO.OR3 and then with an amine HNR1R2, or (3) with phosgene and an alcohol R3OH to form a mixed carbonic acid ester and then with an amine HNR1R2. Chloroformic acid-(2, 2, 2-trischloromethyl)-ethyl ester is prepared by reaction of phosgene with the corresponding hydrin. Pharmacological formulations containing compounds of the invention are mentioned for oral, parenteral and rectal administration. The compounds have sedative and hypnotic properties. Specification 780,713 is referred to.

    Cyclo-octylamine derivatives and their production

    公开(公告)号:GB831185A

    公开(公告)日:1960-03-23

    申请号:GB2701758

    申请日:1958-08-22

    Applicant: BASF AG

    Abstract: The invention comprises cyclo-octylamine derivatives of the general formula wherein R is an aliphatic hydrocarbon radical of 2 to 4 carbon atoms, and any salt of the cyclooctylamine derivatives with an inorganic acid or with an organic acid with 1 to 8 carbon atoms. These salts have high analgesic action and low toxicity. The cyclo-octylamine derivatives are obtained (a) by reacting cyclo-octylamine, cyclo - octanone - oxime, or nitro - cyclooctane with a C3 or C4 ketone with simultaneous hydrogenation; or (b) by reacting cyclooctanone and a C2-C4 primary amine with simultaneous hydrogenation. In Example 1, a mixture of cyclo-octylamine and methyl ethyl ketone, dissolved in ethyl alcohol, is hydrogenated, in the presence of a copperchromium oxide catalyst, at 140 DEG C. and a hydrogen-pressure of 150 atm. The catalyst is filtered-off, the solvent evaporated-off, and the residue distilled under reduced pressure to yield pure cyclo-octyl-secondary butylamine. The example also describes the preparation of the hydrochloride and the succinate of the amine. In Examples 3 and 4, cyclo-octyl-secondary butylamine is prepared by hydrogenating a mixture of cyclo-octanone-oxime and methyl ethyl ketone, or nitrocyclo-octane and methyl ethyl ketone, respectively. In Example 6, cyclo-octyl-isobutylamine is prepared by hydrogenating a mixture of cyclooctanone and isobutylamine. Example 7 describes the preparation of cyclo-octyl-isopropylamine by hydrogenating a mixture of cyclo-octyl-amine and acetone. Example 8 relates to salts of cyclo-octyl-secondary-butylamine with salicyclic, maleic, phthalic, hydroiodic and hydrobromic acids.

    6-ACYLAMINOPHENYL-4,5-DIHYDROPYRIDAZONES

    公开(公告)号:CA990296A

    公开(公告)日:1976-06-01

    申请号:CA142033

    申请日:1972-05-10

    Applicant: BASF AG

    Abstract: 1386150 6 - Acylaminophenyl - 4,5 - dihydropyridazones BADISCHE ANILINSODAFABRIK AG 10 May 1972 [11 May 1971] 21734/72 Heading C2C Novel 6 - acylamino - 4,5 - dihydropyridazone compounds of general Formula (1): in which R is H or C 1-8 alkyl, and X is an amino or ammonium radical containing directly attached to the N atom at least one C atom but not more than one aromatic ring, and acid addition salts thereof, may be prepared by reacting an amine XH or a trialkylamine with a dihydropyridazone of the Formula (2): which in turn may be prepared by reacting compounds of Formula (4) with compounds of Formula (5) to form compounds of Formula (6) which are then cyclized with hydrazine The novel compounds I exhibit pharmaceutical properties, having the effect of lowering blood pressure, dilating the coronary arteries and combating inflammation.

Patent Agency Ranking